These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6097665)

  • 1. Influence of food on the bioavailability of enalapril.
    Swanson BN; Vlasses PH; Ferguson RK; Bergquist PA; Till AE; Irvin JD; Harris K
    J Pharm Sci; 1984 Nov; 73(11):1655-7. PubMed ID: 6097665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.
    Till AE; Gomez HJ; Hichens M; Bolognese JA; McNabb WR; Brooks BA; Noormohamed F; Lant AF
    Biopharm Drug Dispos; 1984; 5(3):273-80. PubMed ID: 6091806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W; Muscará MN; Martins AR; Moreno H; Mendes GB; de Nucci G
    Eur J Clin Pharmacol; 1996; 50(5):399-405. PubMed ID: 8839663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Mojaverian P; Rocci ML; Vlasses PH; Hoholick C; Clementi RA; Ferguson RK
    J Pharm Sci; 1986 Apr; 75(4):395-7. PubMed ID: 3014110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets.
    Moffett BS; DiSanto AR; Espinosa O; Hou J; Colabuono P
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):493-8. PubMed ID: 27129124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.
    Ferguson RK; Vlasses PH; Swanson BN; Mojaverian P; Hichens M; Irvin JD; Huber PB
    Clin Pharmacol Ther; 1982 Jul; 32(1):48-53. PubMed ID: 6282527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays.
    Arafat T; Awad R; Hamad M; Azzam R; Al-Nasan A; Jehanli A; Matalka K
    J Clin Pharm Ther; 2005 Aug; 30(4):319-28. PubMed ID: 15985045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enalapril maleate and a lysine analogue (MK-521): disposition in man.
    Ulm EH; Hichens M; Gomez HJ; Till AE; Hand E; Vassil TC; Biollaz J; Brunner HR; Schelling JL
    Br J Clin Pharmacol; 1982 Sep; 14(3):357-62. PubMed ID: 6289858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Vlasses PH; Larijani GE; Conner DP; Ferguson RK
    Clin Pharm; 1985; 4(1):27-40. PubMed ID: 2982541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.
    Dickstein K; Till AE; Aarsland T; Tjelta K; Abrahamsen AM; Kristianson K; Gomez HJ; Gregg H; Hichens M
    Br J Clin Pharmacol; 1987 Apr; 23(4):403-10. PubMed ID: 3034316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man.
    Ulm EH
    Drug Metab Rev; 1983; 14(1):99-110. PubMed ID: 6301792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of enalapril in congestive heart failure.
    Dickstein K
    Drugs; 1986; 32 Suppl 5():40-4. PubMed ID: 3032562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of the clinical pharmacology of enalapril.
    Davies RO; Gomez HJ; Irvin JD; Walker JF
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):215S-229S. PubMed ID: 6099737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enalapril: a review of human pharmacology.
    Gomez HJ; Cirillo VJ; Irvin JD
    Drugs; 1985; 30 Suppl 1():13-24. PubMed ID: 2994984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
    Edeki T; Johnston A; Li Kam Wa E; Turner P
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes.
    Pang KS; Cherry WF; Terrell JA; Ulm EH
    Drug Metab Dispos; 1984; 12(3):309-13. PubMed ID: 6145558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of enalapril in children and infants with hypertension.
    Wells T; Rippley R; Hogg R; Sakarcan A; Blowey D; Walson P; Vogt B; Delucchi A; Lo MW; Hand E; Panebianco D; Shaw W; Shahinfar S
    J Clin Pharmacol; 2001 Oct; 41(10):1064-74. PubMed ID: 11583474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.
    Biollaz J; Schelling JL; Jacot Des Combes B; Brunner DB; Desponds G; Brunner HR; Ulm EH; Hichens M; Gomez HJ
    Br J Clin Pharmacol; 1982 Sep; 14(3):363-8. PubMed ID: 6289859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation.
    Lo M-W ; McCrea JB; Shadle CR; Hesney M; Chiou R; Cylc D; Yuan AS; Goldberg MR
    Int J Clin Pharmacol Ther; 2000 Jul; 38(7):327-32. PubMed ID: 10919340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.